The transdermal drug delivery systems market was valued at $6,063.85 million in 2019 and is expected to reach $8,415.04 million by 2027. It is expected to grow at a CAGR of 4% from 2021 to 2027. The prevalence of chronic diseases where existing drug delivery systems, such as oral medications, have low efficacy due to primary metabolism of the liver, is leading the market.
A full report of Transdermal Drug Delivery Systems Market available at https://www.orionmarketreports.com/transdermal-drug-delivery-systems-market/53494/
Key Market Players
The key players in the transdermal drug delivery systems market are Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), and GlaxoSmithKline (UK). Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US).
Transdermal Drug Delivery Systems Market Segmentations
By Type of Delivery System
Passive
• Matrix System
• Reservoir System
Active
• Structure Based
• Electrical Based
• Others
By Application
• Analgesics
• Hormone Replacement Therapy
• Cardiovascular Disorders
• Motion Sickness
• Smoking Cessation
• Others
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
